Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA Is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy;El aumento de la expresión del arnm de la enzima convertidora de angiotensina i homóloga (ECA-2) inducido por atorvastatina se asocia a menor fibrosis e hipertrofia ventricular izquierda en un modelo de cardiomiopatía diabética

Revista Peruana de Medicina Experimental y Salud Publica

Volumn 28, Issue 2, 2011, Pages 264-272

  Aguilar, Cristian ^a   Ventura, Freddy ^b   Rodríguez Delfín, Luis ^a,c,d  

^a HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^b UNIVERSIDAD NACIONAL DE TRUJILLO   (Peru)

^c UNIVERSIDAD NACIONAL PEDRO RUIZ GALLO   (Peru)

^d Investigación y Diagnóstico en Genética y Biología Molecular 'GEN MOL'   (Peru)

Author keywords

Cardiomyopathies; Renin angiotensin system; Reverse transcriptase polymerace chain reaction

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ATORVASTATIN; CHOLESTEROL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DISEASE COURSE; DRUG EFFECT; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

EID: 80052180608     PISSN: 17264634     EISSN: 17264642     Source Type: Journal    
DOI: 10.1590/S1726-46342011000200013     Document Type: Article

References (30)

1. Hayat S, Patel B, Khattar R, Malik R. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci. 2004;107:539-57.
2. Adeghate E. Molecular and cellular basis of the etiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem. 2004;261:187-91.
3. Akula A, Kota M, Gopisetty S, Chitrapu R, Kalagara M, Kalagara S, et al. Biochemical, histological and echocardiographic changes during experimental cardiomyopathy in STZ-induced diabetic rats. Pharmacol Res. 2003;48:429-35.
4. Asbun J, Villarreal F. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol. 2006;47:693-700.
5. De Mello WC. Impaired cell communication in the diabetic heart. The role of the renin angiotensin system. Mol Cell Biochem. 2007;296:53-8.
6. Tsutsui H, Matsushima S, Kinugawa S, Ide T, Inoue N, Ohta Y, et al. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res. 2007;30:439-49.
7. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-9.
8. Crackower M, Sarao R, Oudit G, Yagil C, Kozieradzki I, Scanga S, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-8.
9. Donoghue M, Wakimoto H, Maguire C, Acton S, Hales P, Stagliano N, et al. Heart block, ventricular tachycardia, and suden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol. 2003;35:1043-53.
10. Kjekhus J, Pedersen T. The effects of simvastatin of the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3:249-54.
11. Rikitake Y, Liao J. Rho GTPases, statins and nitric oxide. Circ Res. 2005;97:1232-5.
12. Kang B, Mehta J. Rosuvastatin attenuates Ang II-mediated cardiomyocyte hypertrophy via inhibition of LOX-1. Mol Cardiovasc Pharmacol Ther. 2009;14(4):283-91.
13. Riad A, Du J, Stiehl S, Westermann D, Mohr Z, Sobirey M, et al. Low-dose treatment with atorvastatin leads to antioxidative and anti-inflammatory effects in diabetes mellitus. Eur J Pharmacol. 2007;569:204-11.
14. Chen G, Yao L, Lu X, Li L, Hu S. Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in spontaneously hypertensive rats. Acta Pharmacol Sin. 2008;29(10):1181-6.
15. Matsubara L, Narikawa S, Ferreira N, Zornoff L, Matsubara B. Myocardial Remodeling in Chronic Pressure or Volume Overload in the Rat Heart. Arq Bras Cardiol. 2006;86(2):126-30.
16. Reddy G, Enweka C. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem. 1996;29:225-9.
17. Lopez I, Relaño E, Herrera E, Bocos S. Estudio del mecanismo de acción hipolipemiante de la lovastatina en la rata. Clin Invest Arterioscl. 2003;15(6):248-57.
18. Luo J, Zhang W, Zhang G, Guan J, Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Phys. 1999;26:903-8.
19. Wassmann S, Laufs U, Bäumer A, Müller K, Konkol C, Sauer H, et al. Inhibition of geranylgranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646-54.
20. Luo J, Xie F, Zhang W, Ma X, Guan J, Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol. 2001;132:159-64.
21. Hernández O, Pérez D, Navarro J, Sánchez R, Hernández G, Díaz C, et al. Effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-9.
22. Ocaranza M, Rivera P, Jalil J. Increased expression of homologous angiotensin I converting enzyme (ACE2) in the arterial wall of rats with genetically elevated levels of Angiotensin II: effects of candesartan and fasudil. Rev Chil Cardiol. 2008;27(2):173-82.
23. Riva E, Andreoni G, Bianchi R, Latini R, Luvara G, Jeremic G, et al. Changes in diastolic function and collagen content in normotensive and hypertensive rats with longterm streptozotocin-induced diabetes. Pharmacol Res. 1998;37:233-40.
24. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck P, et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation. 1999;99:2750-6.
25. Landau D, Chayat C, Zucker N, Golomb E, Yagil C, Yagil Y, et al. Early blood pressure-independent cardiac changes in diabetic rats. J Endocrinol. 2008;197:75-83.
26. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol. 2005;32(9):697-701.
27. Qin X, Jia C, Pan M, Shen A, Jing H. Effect of atorvastatin on ACE2 expression in pressure overload induced cardiac hypertrophy in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008;33(5):438-42.
28. Aoki H, Izumo S, Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res. 1998;82:666-76.
29. Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A, et al. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol. 2001;21:868-73.
30. Ocaranza M, Rivera P, Jalil J. Inhibition of Rho-kynase decreases systolic blood pressure and activates the vasodilating pathway of the renin angiotensin system in the arterial wall of hypertensive rats. 2008;27(1):65-76.